Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$8.90 USD
-0.44 (-4.71%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $8.91 +0.01 (0.11%) 6:30 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CRBP 8.90 -0.44(-4.71%)
Will CRBP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRBP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRBP
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?
CRBP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold?
3 Unconventional Cannabis Stocks to Watch in 2025
Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High?
Other News for CRBP
Corbus Pharmaceuticals (CRBP) Gears Up for Pivotal Data Presentations in Late 2025
Corbus Pharmaceuticals GAAP EPS of -$1.44 misses by $0.08
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate ...
Corbus Pharmaceuticals reports Q2 EPS ($1.44), consensus ($1.33)
CRBP: B. Riley Maintains Buy Rating with Promising Drug Potential